Astra Wins MedImmune Auction; $15.6 Billion Price Tag Raises Eyebrows

AstraZeneca's move to bolster its biologics portfolio through the acquisition of MedImmune for roughly $15.6 billion illustrates the increasingly high stakes of mergers in the biotech space